Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

ORIC Pharmaceuticals is attractive because its pipeline offers two differentiated shots on goal: rinzimetostat in post-abiraterone mCRPC and enozertinib in atypical EGFR-mutant NSCLC, both supported by encouraging early efficacy and a potentially cleaner safety profile. The company’s recent data, including enozertinib’s 84% confirmed ORR and rinzimetostat’s 47% PSA50 with favorable early rPFS trends, suggest real clinical activity, while the upcoming MEVPRO-1 readout and July 2026 Himalayas-1 initiation provide meaningful catalysts that could validate the platform. Financially, ORIC also appears well positioned with cash runway into 2H28, giving it flexibility to advance multiple programs without immediate financing pressure.

ORIC Pharmaceuticals is viewed negatively because MEVPRO-1 appears to be failing on mechanism, raising doubt that PRC2 inhibition can meaningfully reverse AR resistance at scale, while its safety profile leaves little room for further dose optimization. Competitive pressure is also intensifying as Ex20ins and PACC programs show rapid progress with strong CNS activity, and Pluvicto and JANX007 have already shown PSA50/90 levels above mevro with rPFS of 8.7-8.9 months in more pretreated patients, underscoring the risk that ORIC lacks a clearly differentiated profile ahead of phase 3. Although safety at 50 mg has looked tolerable, grade ≥3 TRAEs rose from 10% to 17% with follow-up and one treatment-related Grade 5 acute kidney injury occurred, while hypercholesterolemia, hypertriglyceridemia, and liver-related toxicity concerns add to regulatory and commercialization risk.